Wells Fargo & Company Enlivex Therapeutics Ltd. Transaction History

Wells Fargo & Company

  • $410 Billion
  • Q1 2024

A detailed history of Wells Fargo & Company transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 9,993 shares of ENLV stock, worth $13,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,993
Previous 9,993 -0.0%
Holding current value
$13,990
Previous $26,000 42.31%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$1.29 - $2.92 $1,433 - $3,244
1,111 Added 12.51%
9,993 $26,000
Q2 2023

Aug 15, 2023
SELL
$2.51 - $3.71 $4,553 - $6,729
-1,814 Reduced 16.96%
8,882 $23,000
Q1 2023

May 12, 2023
SELL
$3.41 - $4.55 $3,580 - $4,777
-1,050 Reduced 8.94%
10,696 $38,000
Q4 2022

Feb 13, 2023
SELL
$3.74 - $4.81 $23,591 - $30,341
-6,308 Reduced 34.94%
11,746 $46,000
Q3 2022

Nov 14, 2022
BUY
$4.11 - $5.87 $23,348 - $33,347
5,681 Added 45.91%
18,054 $77,000
Q2 2022

Aug 12, 2022
SELL
$3.81 - $8.64 $12,348 - $28,002
-3,241 Reduced 20.76%
12,373 $56,000
Q1 2022

May 16, 2022
BUY
$4.92 - $6.66 $16,777 - $22,710
3,410 Added 27.94%
15,614 $87,000
Q4 2021

Feb 14, 2022
SELL
$5.81 - $9.73 $5,600 - $9,379
-964 Reduced 7.32%
12,204 $76,000
Q3 2021

Nov 15, 2021
SELL
$7.43 - $13.86 $46,979 - $87,636
-6,323 Reduced 32.44%
13,168 $130,000
Q2 2021

Aug 16, 2021
BUY
$8.61 - $12.1 $12,915 - $18,150
1,500 Added 8.34%
19,491 $174,000
Q1 2021

May 13, 2021
BUY
$9.26 - $24.0 $164,744 - $426,984
17,791 Added 8895.5%
17,991 $199,000
Q4 2020

Feb 09, 2021
BUY
$8.16 - $14.5 $1,632 - $2,900
200 New
200 $2,000

Others Institutions Holding ENLV

# of Institutions
22
Shares Held
341K
Call Options Held
22.8K
Put Options Held
29.1K
View Full List

About Enlivex Therapeutics Ltd.

ENLV Quotes by TradingView
  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $25.8M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email